Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2008 1
2010 1
2011 5
2012 9
2013 12
2014 13
2015 29
2016 49
2017 88
2018 125
2019 181
2020 254
2021 339
2022 452
2023 471
2024 176

Text availability

Article attribute

Article type

Publication date

Search Results

1,999 results

Results by year

Filters applied: . Clear all
Page 1
Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, Shao ZM. Yang F, et al. Cell Metab. 2023 Jan 3;35(1):84-100.e8. doi: 10.1016/j.cmet.2022.09.021. Epub 2022 Oct 17. Cell Metab. 2023. PMID: 36257316 Free article.
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metabolic pathways in regulating ferroptosis will provide new insights into TNBC therapeutic strategies. ...Clinically, higher GPX4 expression corre …
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metaboli …
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM. Keenan TE, et al. J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. J Natl Compr Canc Netw. 2020. PMID: 32259782 Review.
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast cancer (TNBC), which has sever …
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy o …
Advances in immunotherapy for triple-negative breast cancer.
Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Liu Y, et al. Mol Cancer. 2023 Sep 2;22(1):145. doi: 10.1186/s12943-023-01850-7. Mol Cancer. 2023. PMID: 37660039 Free PMC article. Review.
It also suppresses immunosuppressive molecules, activates or restores immune system function, enhances anti-tumor immune responses, and inhibits the growth f tumor cell. This offers the possibility of reducing mortality in triple-negative breast cancer …
It also suppresses immunosuppressive molecules, activates or restores immune system function, enhances anti-tumor immune responses, and inhi …
Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Zhu Y, et al. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188593. doi: 10.1016/j.bbcan.2021.188593. Epub 2021 Jul 17. Biochim Biophys Acta Rev Cancer. 2021. PMID: 34280474 Review.
Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression. Compared with other subtypes in …
Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking estrogen r …
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Li Y, et al. J Hematol Oncol. 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0. J Hematol Oncol. 2022. PMID: 36038913 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. ...Hence, targeted therapies, such as those targeting DNA repair pathways, androgen receptor signaling pathways, and kinases, …
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a po …
Pathology of triple negative breast cancer.
Borri F, Granaglia A. Borri F, et al. Semin Cancer Biol. 2021 Jul;72:136-145. doi: 10.1016/j.semcancer.2020.06.005. Epub 2020 Jun 13. Semin Cancer Biol. 2021. PMID: 32544511 Review.
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone receptors expression and HER2 gene amplification and represents 24 % of newly diagnosed breast neoplasms. In this review, pathological aspects of …
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone receptors expression an …
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X, Tian T, Yang Y, Chen K, Lei QY, Zhang S, Xu Y, Lv L. Zhang R, et al. Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):e2114851119. doi: 10.1073/pnas.2114851119. Proc Natl Acad Sci U S A. 2022. PMID: 35181605 Free PMC article.
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. ...Moreover, D-mannose-induced PD-L1 degradation also results in …
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative breast cancer …
Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.
Geurts V, Kok M. Geurts V, et al. Curr Treat Options Oncol. 2023 Jun;24(6):628-643. doi: 10.1007/s11864-023-01069-0. Epub 2023 Apr 20. Curr Treat Options Oncol. 2023. PMID: 37079257 Free PMC article. Review.
In approximately 15-20% of the patients diagnosed with breast cancer, it comprises the triple negative (TN) subtype, which until recently lacked targets for specific treatments and is known for its aggressive clinical behavior in patients with metastat …
In approximately 15-20% of the patients diagnosed with breast cancer, it comprises the triple negative (TN) subt …
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M. Agostinetto E, et al. Expert Opin Investig Drugs. 2022 Jun;31(6):567-591. doi: 10.1080/13543784.2022.2049232. Epub 2022 Mar 9. Expert Opin Investig Drugs. 2022. PMID: 35240902 Review.
INTRODUCTION: Triple negative breast cancer (TNBC) is an area of high unmet medical need in terms of new effective treatment strategies. Although breast cancer is traditionally considered a 'cold' tumor type, TNBC is the most appropriate …
INTRODUCTION: Triple negative breast cancer (TNBC) is an area of high unmet medical need in terms of new effecti …
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP. Leon-Ferre RA, et al. BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. BMJ. 2023. PMID: 37253507 Review.
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. ...Furthermore, advances in drug development have led to the approval of antibody-drug conjugates that a …
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest …
1,999 results